Baricitinib in Patients with Rheumatoid Arthritis: BEAM (JADV)

• Research type

  Research Study

• Full title

  Study I4V-MC-JADV is a Phase 3, randomized, double-blind, placebo- and active-controlled, parallel-group study of baricitinib for the treatment of moderately to severely active rheumatoid arthritis during a 52-week treatment period in patients with inadequate response to methotrexate therapy.

• IRAS ID

  119511

• Contact name

  Bruce Kirkham

• Sponsor organisation

  Eli Lilly UK

• Eudract number

  2012-002322-73

• ISRCTN Number

  N//A

• Clinicaltrials.gov Identifier

  N//A

• Research summary

  Baricitinib (LY3009104) is an oral kinase inhibitor that could potentially be an effective therapy for treatment of patients with moderate to severe rheumatoid arthritis (RA). The study aims to confirm the effectiveness, and to continue to define the safety profile, of 4 mg baricitinib when administered once a day to patients with RA who have had an unsatisfactory response to methotrexate therapy.

• REC name

  South Central - Berkshire B Research Ethics Committee

• REC reference

  13/SC/0021

• Date of REC Opinion

  15 Feb 2013

• REC opinion

  Further Information Favourable Opinion